News

Article

Catalent to Invest $9 Million to Establish San Diego Clinical Supply Facility

The new facility will handle clinical supply management, primary and secondary packaging, complex labeling services, clinical storage, distribution, and drug returns and destruction and will include stability chambers.

Catalent announced on Sept. 5, 2019 that it will invest $9 million into a new clinical supply facility in San Diego, CA. The facility will begin operations in the summer of 2020. 

The new facility will provide clinical supply services to pharmaceutical and biopharmaceutical customers and will specialize in services for early-phase clinical trials while enhancing the company’s OptiForm Total Supply service, which offers customers integrated development, clinical supply manufacturing, and distribution. The facility will also handle clinical supply management, primary and secondary packaging, complex labeling services, clinical storage, distribution, and drug returns and destruction and will include stability chambers.

“This investment supports Catalent’s commitment to offering customers greater flexibility and expanded support for early-phase studies,” said Paul Hegwood, president, clinical supply services, in a company press release. “The facility will allow Catalent to provide superior clinical services throughout the western corridor of the [Unites States] and Canada’s drug development region.”

The facility will join two existing Catalent global centers of excellence in oral dose early-phase development in Somerset, NJ, and Nottingham, UK. 

Source: Catalent

 

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content